Severe Asthma in Black Children: Can Testing Guide Care?

What did researchers find about severe asthma in Black children?

Research highlighted by UVA Health on October 15 adds evidence that children with difficult asthma may need closer assessment of their underlying inflammation. The university's team recommends considering inflammatory testing in children whose symptoms remain difficult to manage, regardless of race. [UVA Health research announcement](https://www.uvahealth.com/news/black-children-at-risk-for-severe-form-of-asthma-research-shows).

The study, published online in August in The Journal of Allergy and Clinical Immunology: In Practice, compared 202 children classified as T2-high with 249 classified as T2-low. The T2-high definition combined elevated eosinophils in blood or lung fluid with antibodies indicating sensitization to at least one allergen. These children had more hospital admissions and poorer lung function. Black race remained associated with the inflammatory pattern in adjusted analyses. [Original study](https://doi.org/10.1016/j.jaip.2026.07.042).

The study's observational design limits what those findings establish. An association remaining after statistical adjustment does not demonstrate that race itself causes inflammation or identify a genetic explanation. Nor does it eliminate effects from exposures or social circumstances that were incompletely measured. Because participants already had severe, treatment-resistant asthma, the group proportions should not be interpreted as prevalence estimates for all children.

How can doctors identify type 2 inflammation in childhood asthma?

Type 2 inflammation describes an immune response associated with some forms of asthma. Eosinophils are white blood cells that can participate in this response, while allergen-specific IgE identifies sensitization to particular substances. These measurements provide different information from spirometry, which assesses airflow. The National Heart, Lung, and Blood Institute also describes fractional exhaled nitric oxide testing as a way to detect evidence of airway inflammation. Clinicians interpret these findings together rather than treating one result as a complete diagnosis. [NHLBI asthma diagnosis guidance](https://www.nhlbi.nih.gov/health/asthma/diagnosis).

For families, the reason to request reassessment is persistent trouble: repeated nighttime coughing, increasing reliever use or difficulty keeping up with usual activities. These are recognized signs that asthma may be worsening. A review should include whether the child can use the inhaler correctly and whether the prescribed treatment is controlling symptoms. Identifying inflammation adds information to this assessment; it does not replace attention to everyday treatment and practical barriers to using it. [NHLBI asthma symptoms](https://www.nhlbi.nih.gov/health/asthma/symptoms), [NHLBI treatment guidance](https://www.nhlbi.nih.gov/health/asthma/treatment-action-plan).

Can targeted treatment reduce severe asthma attacks in children?

Earlier clinical trials show why identifying inflammatory patterns can matter. In the separate MUPPITS-2 trial, researchers enrolled 290 children and adolescents aged 6 to 17 with asthma prone to attacks and elevated blood eosinophils. Participants lived in disadvantaged urban neighborhoods; most were Black or Hispanic. Adding mepolizumab to guideline-based care reduced the asthma attack rate by 27% compared with placebo over approximately one year. This was a relative reduction in attack frequency, not a cure or a guarantee that an individual child would avoid attacks. [NIH report on MUPPITS-2](https://www.nih.gov/news-events/news-releases/monoclonal-antibody-reduces-asthma-attacks-urban-youth).

Both trial groups experienced improved asthma control, emphasizing the contribution of regular care alongside targeted medication. NIH and the manufacturer funded the trial. Its findings support treatment for appropriately selected patients, but they do not establish that the testing approach proposed by the UVA researchers will improve outcomes. That question requires direct evaluation. [NIH trial findings](https://www.nih.gov/news-events/news-releases/monoclonal-antibody-reduces-asthma-attacks-urban-youth).

Families should continue prescribed treatment while discussing persistent symptoms with their child's clinician. An individualized asthma action plan should explain which medicines to use, how to recognize deterioration and when to seek emergency help. Testing is most useful when it leads to a clear treatment decision and follow-up assessment of whether the child is improving. [NHLBI treatment and action plan guidance](https://www.nhlbi.nih.gov/health/asthma/treatment-action-plan).